Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer
- 31 July 1991
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (7) , 849-852
- https://doi.org/10.1016/0277-5379(91)90132-w
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.Journal of Clinical Oncology, 1991
- A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.Journal of Clinical Oncology, 1990
- A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.Journal of Clinical Oncology, 1988
- Methylprednisolone for the Control of CMF-Induced EmesisAmerican Journal of Clinical Oncology, 1987
- Brain Peptides: What, Where, And Why?Science, 1983
- Methylprednisolone as an AntiemeticNew England Journal of Medicine, 1981
- The two‐period cross‐over clinical trial.British Journal of Clinical Pharmacology, 1979
- Interaction between acth fragments, brain opiate receptors and morphine-induced analgesiaEuropean Journal of Pharmacology, 1976
- Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptorsEuropean Journal of Pharmacology, 1976
- Adrenocorticotrophic action of long-acting tetracosactrin compared with corticotrophin-gelBMJ, 1967